Encompass Health ((EHC)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Encompass Health struck a confident tone on its latest earnings call, highlighting broad-based strength in revenue, profitability, cash generation and clinical quality. Management acknowledged some manageable headwinds, but emphasized that capacity additions, disciplined capital deployment and operational improvements support a higher long-term earnings trajectory.
Top-Line and Profitability Growth
Encompass Health posted Q1 revenue of $1.59 billion, up 9% year over year, while adjusted EBITDA climbed 11.2% to $348.8 million. On the back of this momentum, the company raised its 2026 outlook, now targeting $6.375–$6.470 billion in net operating revenue and $1.35–$1.38 billion in adjusted EBITDA.
Strong Discharge and Pricing Trends
Total discharges increased 4.3% with same-store discharges up 1.6%, underscoring resilient demand for inpatient rehabilitation services. Net revenue per discharge rose 3.7%, helped by a favorable patient mix and a positive Medicare SSI adjustment, providing a solid pricing tailwind.
Outstanding Clinical Outcomes and Quality Metrics
Clinical quality remains a key differentiator, with discharge-to-community rising 50 basis points to 84.5%, well ahead of industry norms. Discharge-to-acute and discharge-to-SNF both improved, signaling better patient outcomes and strengthening the company’s value proposition to payers and referring hospitals.
Workforce Stability and Lower Premium Labor
Staffing trends improved meaningfully, as RN turnover fell to 17.8% from 20.2%, the best level in more than a decade, and therapist turnover declined to 6.4%. This stability contributed to a 9.4% reduction in premium labor spend and pushed contract labor to just 1.2% of total FTEs.
Capacity Expansion and Development Pipeline
The company opened a new 49-bed hospital in Irmo, South Carolina and added 44 beds to existing facilities during Q1, directly addressing tight capacity. Looking ahead to 2026, management plans seven more hospitals with roughly 340 beds plus 100–150 additional beds, and is building a small-format strategy with a multi-year pipeline.
Strong Cash Generation and Capital Allocation
Adjusted free cash flow reached $194 million in Q1, giving Encompass Health ample flexibility to fund growth and shareholder returns. The company repurchased about 708,000 shares for $71.6 million, maintained a $0.19 per share dividend and ended the quarter with conservative net leverage of 1.9x.
Operational Efficiency and Digital/Analytics Initiatives
Salary, wages and benefits per FTE increased 3.7% as the company invested in clinical career ladders and talent retention. At the same time, Encompass Health is rolling out Palantir-enabled analytics to improve market selection, real estate decisions, revenue cycle efficiency and documentation productivity.
Potential Favorable Medicare Pricing Update
The proposed 2027 IRF rule from CMS includes a net market basket update of 2.4%, which management believes could translate into a similar Medicare price increase beginning in late 2026. While still subject to finalization, such an update would add another layer of rate support on top of current pricing gains.
Unit Closures Depressed Volume
Not all volume trends were positive, as the closure of four hosted units, including three IRF units inside acute-care hospitals, trimmed discharge growth by about 85 basis points in Q1. An additional 18-bed hosted unit is slated to close in early 2027, but management expects consolidation strategies to recapture some of this volume.
Bad Debt Increase from Legacy Claim Write-Offs
Bad debt expense ticked up 20 basis points to 2.2% of revenue, driven mainly by write-offs of legacy 2013 claims tied to an audit appeal. Management framed this as a one-time clean-up item rather than a sign of worsening collections, suggesting limited impact on ongoing earnings quality.
Medicare Advantage Utilization Headwinds
The company continues to navigate tough authorization and utilization management practices from Medicare Advantage plans, which are pressuring admissions in certain markets. However, MA penetration has plateaued around the low-50% range and has even slipped in some states, creating mixed but potentially lessening volume pressure over time.
Occupancy Constraints in High-Demand Markets
Average occupancy stood at a healthy 78.7%, yet about 35% of hospitals ran above 90% occupancy with an average of 95%, effectively capping growth in those locations. These constraints underscore the urgency of adding beds and developing smaller hospitals to unlock further same-store discharge gains.
Regulatory and Implementation Risk
Management highlighted several evolving regulatory dynamics, including TEAM implementation and the expansion of review programs into new states, as potential sources of short-term disruption. While these changes could introduce administrative burdens and timing issues, they are viewed as manageable within the broader growth story.
Timing and Cash Tax/Interest Impacts on Free Cash Flow
Free cash flow guidance was nudged down slightly due to higher interest costs of roughly $5 million and increased cash tax payments tied to asset sales and legal recoveries. One-time proceeds of about $40 million help offset the cash outlay, and the company still expects robust free cash flow relative to its growth capital plans.
Guidance and Outlook
Encompass Health raised its 2026 guidance, projecting net operating revenue of $6.375–$6.470 billion, adjusted EBITDA of $1.35–$1.38 billion and adjusted EPS of $5.89–$6.11. The outlook assumes continued discharge growth, modest pricing gains, growth CapEx around a $725 million midpoint and free cash flow near an $818 million midpoint, alongside ongoing new hospital openings and bed expansions.
Encompass Health’s call painted a picture of a disciplined growth company balancing strong fundamentals with measured risk management. With rising earnings guidance, improving labor metrics, a deep development pipeline and resilient demand, management conveyed confidence that the positives meaningfully outweigh near-term headwinds for long-term investors.